These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16741971)

  • 21. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma.
    Kaplan CD; Krüger JA; Zhou H; Luo Y; Xiang R; Reisfeld RA
    Vaccine; 2006 Nov; 24(47-48):6994-7002. PubMed ID: 17050049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of cancer radiation therapy by use of adenovirus-mediated secretable glucose-regulated protein 94/gp96 expression.
    Liu S; Wang H; Yang Z; Kon T; Zhu J; Cao Y; Li F; Kirkpatrick J; Nicchitta CV; Li CY
    Cancer Res; 2005 Oct; 65(20):9126-31. PubMed ID: 16230366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.
    Mkrtichyan M; Ghochikyan A; Davtyan H; Movsesyan N; Loukinov D; Lobanenkov V; Cribbs DH; Laust AK; Nelson EL; Agadjanyan MG
    Cell Immunol; 2011; 270(2):188-97. PubMed ID: 21641588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I.
    Cuesta AM; Suárez E; Larsen M; Jensen KB; Sanz L; Compte M; Kristensen P; Alvarez-Vallina L
    Immunology; 2006 Apr; 117(4):502-6. PubMed ID: 16556264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
    Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
    Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of the embryo/cancer gene ECSA(DPPA2), the cancer/testis gene BORIS and the pluripotency structural gene OCT4, in human preimplantation development.
    Monk M; Hitchins M; Hawes S
    Mol Hum Reprod; 2008 Jun; 14(6):347-55. PubMed ID: 18467432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
    Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA minigene vaccination for adjuvant neuroblastoma therapy.
    Lode HN; Huebener N; Zeng Y; Fest S; Weixler S; Gaedicke G
    Ann N Y Acad Sci; 2004 Dec; 1028():113-21. PubMed ID: 15650237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors.
    Hoffmann D; Bayer W; Wildner O
    Int J Mol Med; 2007 Nov; 20(5):673-81. PubMed ID: 17912460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
    Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
    Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.
    Dharmapuri S; Aurisicchio L; Neuner P; Verdirame M; Ciliberto G; La Monica N
    Cancer Gene Ther; 2009 May; 16(5):462-72. PubMed ID: 18989354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.
    Tiffen JC; Bailey CG; Marshall AD; Metierre C; Feng Y; Wang Q; Watson SL; Holst J; Rasko JE
    Int J Cancer; 2013 Oct; 133(7):1603-13. PubMed ID: 23553099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development.
    Gjerstorff MF; Kock K; Nielsen O; Ditzel HJ
    Hum Reprod; 2007 Apr; 22(4):953-60. PubMed ID: 17208940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
    Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
    Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model.
    Fang J; Wang G; Yang Q; Song J; Wang Y; Wang L
    Vaccine; 2005 Sep; 23(40):4860-6. PubMed ID: 16029917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
    J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.